Show simple item record

dc.contributor.authorTokaca, Nen_US
dc.contributor.authorWotherspoon, Aen_US
dc.contributor.authorNicholson, AGen_US
dc.contributor.authorFotiadis, Nen_US
dc.contributor.authorThompson, Len_US
dc.contributor.authorPopat, Sen_US
dc.date.accessioned2018-02-16T09:30:11Z
dc.date.issued2017-09en_US
dc.identifier.citationLung cancer (Amsterdam, Netherlands), 2017, 111 pp. 65 - 68en_US
dc.identifier.issn0169-5002en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/1152
dc.identifier.eissn1872-8332en_US
dc.identifier.doi10.1016/j.lungcan.2017.07.012en_US
dc.description.abstractSmall cell transformation is a rare but well recognised mechanism of acquired resistance to EGFR-TKI therapy in EGFR-mutated NSCLC, but optimal drug therapy thereof is unknown. Nivolumab has demonstrated activity in relapsed de novo small cell lung cancer in early phase trials. Here, we report a case of transformed EGFR-mutant SCLC treated with nivolumab with no benefit.en_US
dc.formatPrint-Electronicen_US
dc.format.extent65 - 68en_US
dc.languageengen_US
dc.language.isoengen_US
dc.subjectHumansen_US
dc.subjectCarcinoma, Non-Small-Cell Lungen_US
dc.subjectLung Neoplasmsen_US
dc.subjectCell Transformation, Neoplasticen_US
dc.subjectDisease Progressionen_US
dc.subjectReceptor, Epidermal Growth Factoren_US
dc.subjectAntineoplastic Combined Chemotherapy Protocolsen_US
dc.subjectAntibodies, Monoclonalen_US
dc.subjectBiopsyen_US
dc.subjectTreatment Outcomeen_US
dc.subjectDrug Resistance, Neoplasmen_US
dc.subjectMutationen_US
dc.subjectMiddle Ageden_US
dc.subjectFemaleen_US
dc.subjectSmall Cell Lung Carcinomaen_US
dc.subjectPositron Emission Tomography Computed Tomographyen_US
dc.titleLack of response to nivolumab in a patient with EGFR-mutant non-small cell lung cancer adenocarcinoma sub-type transformed to small cell lung cancer.en_US
dc.typeJournal Article
dcterms.dateAccepted2017-07-09en_US
rioxxterms.versionofrecord10.1016/j.lungcan.2017.07.012en_US
rioxxterms.licenseref.startdate2017-09en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfLung cancer (Amsterdam, Netherlands)en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology/Thoracic Oncology (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublisheden_US
pubs.volume111en_US
pubs.embargo.termsNot knownen_US
icr.researchteamThoracic Oncologyen_US
dc.contributor.icrauthorPopat, Sanjayen_US
dc.contributor.icrauthorMarsden,en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record